Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Magnified Learning offers consulting, educational services

October 2025—Magnified Learning offers consulting services across the spectrum of health care operations, including supply chain management, revenue cycle optimization, operational excellence, and organizational change management. The company’s approach leverages next-generation Lean Six Sigma, clinical integration strategies, and advanced technology platforms to create a sustainable alignment between operational performance and financial outcomes. Magnified Learning also offers online certification programs that feature sophisticated online learning management systems with self-paced curricula, comprehensive content previews, and embedded assessment tools compatible across all major operating systems. Each certification includes continuous learning pathways and recertification opportunities.

Quest introduces testing for Oropouche virus

September 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes. The viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika, and chikungunya. Quest’s laboratory in San Juan Capistrano, Calif., will perform the test using PCR technology, with serology testing to follow later this quarter.

C2N launches RUO blood tests for Alzheimer’s disease

September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer’s disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.

Bruker MALDI Biotyper systems awarded ACT label

September 2025—Bruker’s MALDI Biotyper Sirius and Sirius One systems have been awarded the My Green Lab ACT Ecolabel. The MALDI Biotyper systems for microbial identification received an Environmental Impact Factor score of 26.8 (EU and U.K.) and 35.4 (United States).

Agilent expands Dako Omnis family

September 2025—Agilent Technologies is introducing three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements. The Dako Omnis 110 is for low- to medium-volume labs and delivers up to 110 immunohistochemistry slides per day. The Dako Omnis 165 is engineered for medium-high volume labs and has a throughput of up to 165 IHC slides per day, and the 165 Duo has the capacity to run IHC and in situ hybridization slides. All models feature continuous, case-based processing and shared reagents. A newly integrated direct connection for deionized water and nonhazardous waste reduces handling time.

FDA approves Oncomine Dx Express for Zegfrovy

September 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test, an in vitro diagnostic assay, for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes.

Proscia releases laboratory leadership report

September 2025—Proscia partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories and published a report on the findings. The “2025 Laboratory Leadership Report: Insights on Digital Pathology, AI, and Precision Medicine” finds that 38 percent of laboratory leaders cite staffing shortages as their biggest challenge and 31 percent cite declining reimbursement as their top concern. The top-ranked opportunities for labs are automation to drive efficiency (30 percent), molecular and genetic testing (29 percent), and artificial intelligence (25 percent).

Qiagen expands portfolio for MRD testing with strategic partnerships

September 2025—Qiagen is expanding its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease testing in clinical trials to support pharma co-development projects for companion diagnostics. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with Qiagen to create companion diagnostics for MRD testing in solid tumors. The assays, for use on the QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity.

ArteraAI Prostate gets breakthrough device designation

September 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer. ArteraAI Prostate analyzes digital pathology images of a patient’s prostate cancer biopsy slide to prognosticate long-term outcomes, such as 10-year risk of distant metastasis and prostate-cancer specific mortality, to help clinicians determine the most appropriate treatment option.

Bio-Rad launches four ddPCR platforms

September 2025—Bio-Rad Laboratories has launched four Droplet Digital PCR platforms, which include the company’s QX Continuum ddPCR system and the QX700 series of ddPCR platforms, acquired as part of Bio-Rad’s recent purchase of Stilla Technologies. The QX Continuum ddPCR system is designed for translational research applications and features a qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. The QX700 series consists of three ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, can process more than 700 samples per day, and include easy-to-use software for streamlined data interpretation.

MARKETPLACE

TRENDING